HLS Therapeutics (TSE:HLS) Raised to Buy at Canaccord Genuity Group

HLS Therapeutics (TSE:HLS) was upgraded by equities research analysts at Canaccord Genuity Group from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday,BayStreet.CA reports.

HLS Therapeutics Stock Down 3.3%

Shares of HLS traded down C$0.13 during trading hours on Thursday, hitting C$3.85. The company had a trading volume of 211,987 shares, compared to its average volume of 21,830. The company has a current ratio of 1.00, a quick ratio of 1.01 and a debt-to-equity ratio of 75.00. The company has a market capitalization of C$120.41 million, a PE ratio of -12.03 and a beta of -0.18. HLS Therapeutics has a one year low of C$3.81 and a one year high of C$5.77. The company’s fifty day moving average price is C$4.24 and its two-hundred day moving average price is C$4.42.

HLS Therapeutics (TSE:HLS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported C($0.03) earnings per share for the quarter. The business had revenue of C$14.67 million during the quarter. HLS Therapeutics had a negative return on equity of 16.54% and a negative net margin of 18.42%.During the same period last year, the firm earned ($0.09) earnings per share. As a group, equities analysts forecast that HLS Therapeutics will post -0.12 earnings per share for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.